Novel tetrakis–phthalocyanines bearing pyrimidine derivative: crystal XRD analysis, enzyme inhibition, molecular docking, and anticancer effects

Author(s):  
Armağan Günsel ◽  
Bilge Yazar ◽  
Parham Taslimi ◽  
Yavuz Erden ◽  
Tugba Taskin-Tok ◽  
...  
2021 ◽  
Vol 152 (2) ◽  
pp. 251-261
Author(s):  
Gurusamy Sankararaj Senthilkumar ◽  
Murugesan Sankarganesh ◽  
Jeyraj Dhaveethu Raja ◽  
Arumugam Sakthivel ◽  
Rajadurai Vijay Solomon ◽  
...  

2021 ◽  
Vol 36 (1) ◽  
pp. 618-626 ◽  
Author(s):  
Fatema R. Saber ◽  
Rehab M. Ashour ◽  
Ali M. El-Halawany ◽  
Mohamad Fawzi Mahomoodally ◽  
Gunes Ak ◽  
...  

2021 ◽  
Vol 25 (7) ◽  
pp. 138-146
Author(s):  
E. Laxminarayana ◽  
P. Bhasker ◽  
D. Ramesh ◽  
Md. Rafeeq ◽  
B. Srinivasa Reddy

compound 2-((1H-benzo[d]imidazol-2-yl)thio)acetic acid (1) with o-aminobenzamide (2) gave compound (2-[1-(1H-benzimidazol-2-yl)-ethylsulfanyl]-3H-quinazolin-4-one (3). 3 could also be syntehsized by an alternative two routes scheme 2 and scheme 3. It appears from scheme 3 that it is giving good yields under green and eco-friendly conditions using PEG-600 (polyethylent glycol). Compound 10 was synthesized in two routes scheme4 and scheme 5. It appears from Route B (Scheme 4) that it is giving good yields: alkylation followed by oxidation in route A followed by alkylation in PEG-600 used as a green solvent. The total sequence of reactions has been carried out using eco-friendly and green conditions. Further, anticancer activity was carried out by using docking studies and binding conformation of active compounds of 3, 8, 9 and 10. The results show that 3 and 9 have potential to be developed as chemotherapeutic agents and compounds 3, 9 molecule showed best fit, potent dock score when compared with doxorubicin.


2019 ◽  
Vol 91 ◽  
pp. 103138 ◽  
Author(s):  
Mubashir Hassan ◽  
Muhammad Athar Abbasi ◽  
Aziz-ur-Rehman ◽  
Sabahat Zahra Siddiqui ◽  
Saba Shahzadi ◽  
...  

2021 ◽  
Author(s):  
SHAIK IBRAHIM KHALIVULLA ◽  
Kokkanti Mallikarjuna

Abstract The Dementia disease is characterised by neuropsychiatric disturbances due to lack of proper synaptic communication between neurons causing the cognitive behavioural problems. The Alzheimer’s disease (AD) in elderly population is one of the several forms of Dementia. Recent data by World Health Organisation indicates that nearly 10 million people are getting dementia every year, of which 60-70% accounts for AD. The etiology of AD involves the formation of amyloid-β plaques and neurofibrillary Tau tangles in the brain resulting in the death of neural cells. There is no permanent solution for AD treatment, except the FDA approved drugs like galantamine, donepezil, rivastigmine and memantine that are normally associated with side effects. At this juncture, cerebrosides, the natural secondary metabolites identified from different taxa with potential neuroprotective effects offer a promising scope for the treatment of AD. In this paper, cerebrosides reported from all taxa are pooled up along with their functions and listed. The review of literature revealed that Cerebrosides can increase the cognitive functions by regulating or interacting with the N-methyl-d-aspartate (NMDA) calcium ion (Ca2+) channels at post-synaptic receptor; nitric oxide (NO); Bcl2, Bax, amyloid precursor (APP) and Tau proteins; brain-derived neurotrophic factor (BDNF) and cAMP- response element-binding proteins (CREB).This indicates that the Cerebrosides could be potential therapeutic agents for the protection of neurons involved in neurodegenerative disease like Alzheimer’s disease. The current neuroprotective drugs are AChE inhibitors; hence, in the present investigation, in silico molecular docking study on cerebrosides for the inhibition of AChE was assessed to find out their capacity to interact with an active catalytic site of AChE. The results of present investigation revealed that all 22 cerebrosides selected for this work interacted with catalytic active site of AChE measured in terms of Gibbs free binding energy. Of all the cerebrosides assessed, compound 6 exhibited strong interaction, followed by 15. This is the first report of molecular docking study on cerebrosides for AChE enzyme inhibition for treatment of Alzheimer’s disease. Nevertheless, detailed in vitro and in vivo, biochemical and molecular investigations are needed to bring them to useful form.


Sign in / Sign up

Export Citation Format

Share Document